Blog
The case for "biotech paranoia"
Biotechs need to get anxious - really anxious - about how changes in the industry will affect Pharma deal-making.
Drug pricing is the new Big Pharma giant-killer
Is the new contracting deal in hepatitis C a meaningless blip, or the “end of days” for biopharma? (Spoiler alert: "no” and “no”.)
You can't have value-based drug pricing without value
Think you can charge a lot more than generics when your drug is only a little bit better? Think again.
Making clinical development more investable with “financially adaptive trials”
Clinical trials are a terrible investment. But fear not – in our NRDD article, we show a path forward.
Where's the commercial innovation in pharma?
Pharma commercial teams are doing business like it's 2004 ... or maybe even 1994. It's time for a reboot.
Should pharma R&D and commercial "just be friends"?
GlaxoSmithKline is giving up its commercial presence in oncology, but keeping cancer R&D. This could be a huge deal, and a harbinger of things to come.
From bedside to bench and back again: Review of “Cured” by Nathalia Holt
In HIV and many other areas of biopharma, there are no shortcuts - sometimes science progresses a single patient at a time.
Baby biotech grows up: Review of "The Antidote" by Barry Werth
How do you build a drug company? Barry Werth continues the story of Vertex's birth and teenage years that he started with "Billion Dollar Molecule".
"Saving the winners" to improve pharma R&D
Adaptive trials could be a way to improve the pharma industry's dismal R&D success rates.
The future of pharma sales reps
Can you think of a good reason to have a Pharma sales force? Neither can I.